FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a method for the destruction of malignant cells in an individual, comprising administering to the individual a therapeutically effective amount of a combination of siRNA against TGF-beta 1 and siRNA against Cox-2, where the combination is administered together with an inhibitor of immune checkpoints for the treatment of malignant neoplasms.
EFFECT: treatment of a malignant neoplasm using miRNA molecules that inhibit TGF-beta 1 and Cox-2 in combination with an inhibitor of immune checkpoints.
27 cl, 8 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPY METHODS BASED ON CAR T-CELLS WITH INCREASED EFFICIENCY | 2016 |
|
RU2788131C2 |
| CANCER IMMUNOTHERAPY | 2014 |
|
RU2744194C2 |
| METHODS OF TREATING COLORECTAL CANCER | 2014 |
|
RU2674147C2 |
| COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS | 2007 |
|
RU2540490C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS AGAINST MALIGNANT TUMORS WITH RNAi MOLECULES DIRECTED AGAINST Hsp47 | 2015 |
|
RU2756253C2 |
| TREATMENT OF PANCREATIC DEVELOPMENTAL GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO PANCREATIC DEVELOPMENTAL GENE | 2011 |
|
RU2612161C2 |
| COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS | 2007 |
|
RU2478400C2 |
| ANTI-HUMAN 4-1BB ANTIBODIES AND USE THEREOF | 2018 |
|
RU2725811C1 |
| ANTIBODIES AGAINST HUMAN 4-1BB AND THEIR USE | 2018 |
|
RU2777573C2 |
| IMPROVED IMMUNE CELLS WITH DOUBLE shRNA AND COMPOSITIONS CONTAINING THEM | 2019 |
|
RU2793922C2 |
